Matinas BioPharma Holdings, Inc. (NYSE:MTNB)’s traded shares stood at 2,114,112 during the last session, with the company’s beta value hitting 2.77. At the close of trading, the stock’s price was $0.81, to imply an increase of 4.91% or $0.03 in intraday trading. The MTNB share’s 52-week high remains $2.49, putting it -207.41% down since that peak but still an impressive +39.51% since price per share fell to its 52-week low of $0.49. The company has a valuation of $164.38 Million, with an average of 1.57 Million shares in intraday trading volume over the past 10 days and average of 1.61 Million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Matinas BioPharma Holdings, Inc. (MTNB), translating to a mean rating of 1.8. Of 6 analyst(s) looking at the stock, none analyst(s) give MTNB a Sell rating. None of those analysts rate the stock as Overweight while no one advise Hold as 6 recommend it as a Buy. None analyst(s) have given it an Underweight rating. Estimates put the company’s earnings per share at -$0.03.
Matinas BioPharma Holdings, Inc. (NYSE:MTNB) trade information
After registering a 4.91% upside on the day, Matinas BioPharma Holdings, Inc. (MTNB) has traded green over the past five days. The stock hit a weekly high of $0.82 this Friday, Nov 20, jumping 1.72% in its intraday price action. The 5-day price performance for the stock is 0.35%, and -6.71% over 30 days. With these gigs, the year-to-date price performance is -64.5%. Short interest in Matinas BioPharma Holdings, Inc. (NYSE:MTNB) saw shorts transact 16.7 Million shares and set a 10.37 days time to cover.
Analysts on Wall Street suggest a consensus price target of $3.38, implying an increase of 317.28% to the stock’s current value. The extremes give us $1.8 and $5 for target low and target high price respectively. As such, MTNB is trading +517.28% off suggested target high and 122.22% from its likely low.
Matinas BioPharma Holdings, Inc. (MTNB) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 16.9% for the past 5-year period. While 2020 is set for a 17.5% return in earnings, projections for the next 5 years are at 0% annually.
Matinas BioPharma Holdings, Inc. (NYSE:MTNB)’s Major holders
Matinas BioPharma Holdings, Inc. insiders hold 7.72% of total outstanding shares, with institutional holders owning 23.49% of the shares at 25.46% float percentage. In total, 66 institutions holds shares in the company, led by Boxer Capital, LLC. As of Sep 29 this year, the company held over 11.48 Million shares (or 5.76% of shares), all amounting to roughly $8.79 Million.
The next major institution holding the largest number of shares is Vivo Capital, LLC with 11.28 Million shares, or about 5.66% of shares outstanding. As of the market price on 44103, these shares were worth $8.64 Million.
We also have Vanguard Total Stock Market Index Fund and USAA Mutual Fund Tr-Science & Technology Fund as the top two Mutual Funds with the largest holdings of the Matinas BioPharma Holdings, Inc. (MTNB) shares. Going by data provided on 44011, Vanguard Total Stock Market Index Fund holds roughly 5,112,722 shares. This is just over 2.57% of the total shares, with a market valuation of $3.95 Million. Data from the same date shows that the other fund manager holds a little less at 2.27 Million, or 1.14% of the shares, all valued at about $1.77 Million.